The estimated Net Worth of Nur Nicholson is at least $4.05 Milion dollars as of 13 March 2024. Ms Nicholson owns over 11,220 units of Apellis Pharmaceuticals Inc stock worth over $2,159,169 and over the last 4 years she sold APLS stock worth over $1,892,886.
Ms has made over 5 trades of the Apellis Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she sold 11,220 units of APLS stock worth $645,823 on 13 March 2024.
The largest trade she's ever made was selling 20,350 units of Apellis Pharmaceuticals Inc stock on 18 September 2023 worth over $900,895. On average, Ms trades about 3,071 units every 15 days since 2021. As of 13 March 2024 she still owns at least 56,287 units of Apellis Pharmaceuticals Inc stock.
You can see the complete history of Ms Nicholson stock trades at the bottom of the page.
Nur Nicholson is the Chief Technical Operations Officer at Apellis Pharmaceuticals Inc.
Nur's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.
Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois oraz Pascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include: